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BACKGROUND: Passive therapy with convalescent
plasma provides an early opportunity to intervene in
Ebola virus disease (EVD). Methods for field screening
and selection of potential donors and quantifying plasma
antibody are needed.
STUDY DESIGN AND METHODS: Recombinant
Ebola virus glycoprotein (EBOVGP) was formatted into
immunoglobulin G-capture, competitive, and double-
antigen bridging enzyme immunoassays (EIAs). EVD
survivors in Freetown, Sierra Leone, were recruited as
potential plasma donors and assessed locally using sera
alone and/or paired sera and oral fluids (ORFs).
Uninfected controls comprised unexposed Gambians and
communities in Western Area, Sierra Leone. Antibody
neutralization in selected sera was measured
retrospectively in a pseudotype virus assay.
RESULTS: A total of 115 potential donors were
considered for enrollment: 110 plasma samples were
concordantly reactive in the three EIAs; three were
concordantly unreactive and two were reactive in two of
three EIAs (98.2% agreement; 95% confidence interval
[CI], 93.9%-99.8%). In 88 donors with paired ORF and
plasma, G-capture EIA reactivity correlated well in the two
analytes (R25 0.795). Plasma and ORF from 44
Gambians were unreactive. ORF samples from 338 of 339
unexposed Western Area community controls were
unreactive (specificity, 99.7%; 95% CI, 98.4%-99.7%);
ORF samples from 113 of 116 Kerry Town EVD survivors
were reactive (sensitivity, 97.4%; 95% CI, 92.5%-99.5%).
Strong reactivity in G-capture and/or competitive EIAs
identified donors with high plasma EBOVGP antibody
levels in the double-antigen bridging assay, correlating with
high levels of neutralizing antibody.
CONCLUSIONS: In-field testing can qualify
convalescent donors for providing high-titer antibody.
B
y late 2014 the outbreak of Ebola virus disease
(EVD) was unchecked in Guinea, Liberia, and
Sierra Leone. The potential efficacy of conva-
lescent plasma (CP) as a treatment for EVD,
first described in the 1995 Kikwit outbreak,1-3 led the
World Health Organization (WHO) to consider devel-
opment of CP therapy a priority.4,5 CP has been used
for other viral infections3 and we have previously shown6
the importance of serologic confirmation of potential
plasma donors rather than relying on a syndromic diag-
nosis alone.
ABBREVIATIONS: CP 5 convalescent plasma; DABA 5
double-antigen bridging assay; EBOV 5 Ebola virus; ETU 5
Ebola treatment unit; EVD 5 Ebola virus disease; GMT 5
geometric mean titer; GP 5 glycoprotein; IC50 5 50%
reduction of virus infection; NOD 5 normalized optical
density; ORF(s) 5 oral fluid(s); TM 5 transport medium.
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The antibody response after clinical EVD appears
long-lived7 and correlates with the presence of neutraliz-
ing antibody. Nonhuman primate studies have shown that
antibody to EBOV envelope glycoprotein (EBOV GP) pro-
tected against disease progression. A priori, and supported
by these studies in nonhuman primates,9 we decided to
ensure that human CP was drawn only from donors with
plasma levels of EBOV GP antibody likely also to contain
high levels of neutralizing antibody. To deliver this aspira-
tion new serologic methods for the detection and qualifica-
tion of immune donors were needed.10 The development
of assays was undertaken, including for noninvasive
samples, to provide initial screening as well as the identi-
fication of those seropositive potential donors with
higher antibody levels. In spite of previous attempts to
use nonblood analytes including oral fluid (ORF) for
Ebola serology being unsuccessful,11 recognizing the
widespread use of ORF in clinical virology,12 we also
elected to pursue this approach. The enzyme immunoas-
says (EIAs) had to be specific and semiquantitative, pref-
erably including noninvasive protocols, and sufficiently
robust to be transported and used in the field in the
absence of a cold chain. A series of EIA formats were
constructed using the recombinant EBOV GP antigen
employed by Qiu and colleagues.9 The use of these EIAs,
including a noninvasive test using ORF, for facilitating
the identification, recruitment, and qualification of con-
valescent blood donors as a potential source of therapeu-
tic CP is described.
MATERIALS AND METHODS
Potential donors
The study “Convalescent plasma for early Ebola virus disease in
Sierra Leone” (ISRCTN13990511 and PACTR201602001355272)
was approved by the Sierra Leone Ethics and Scientific
Review Committee, authorized by Pharmacy Board of
Sierra Leone (PBSL/CTAN/MOHS-CST001) and spon-
sored by the University of Liverpool. The protocol is avail-
able on request (m.g.semple@liverpool.ac.uk).
Ebola virus disease survivors with certificates (issued
by Ebola Treatment Centers on discharge) were recruited
as potential donors through Military Hospital 34, Free-
town, and the Sierra Leone Association of Ebola Survivors.
Of 130 recruited and consented (Fig. 1), on average 6.1
months (range, 1-15 months; midquartiles, 4-8 months)
after discharge, 12 were referred to the Ebola Survivors’
Clinic because of possible post EVD sequelae.13 A total of
118 well volunteers were referred to the blood bank in
Freetown for final assessment. Three were excluded
because of hepatitis B virus infection. The remaining 115
provided written consent to become qualified donors, giv-
ing 315 plasma samples and 205 ORF samples overall. In
addition the first (#15/220) and the second (#15/252)
WHO standards from the National Institute of Biological
Standards and Controls were included as controls.
Unexposed controls, The Gambia
Forty-four individuals were enrolled by the Medical
Research Council Unit, The Gambia, into a malaria field
study and serum and ORF samples archived. Approval
was given to test these locally for antibody to EBOV.
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Survivors and unexposed community controls,
Sierra Leone
As part of a separate study on transmission within house-
holds14 ORF samples were taken from 116 polymerase chain
reaction (PCR)-confirmed EBV survivors from Kerry Town
Ebola Treatment Center, and 339 healthy volunteers living
in three communities in Western Area Sierra Leone, which
had no recorded cases of EVD. These samples were analyzed
in Makeni, Sierra Leone. This study was approved by the
Sierra Leone Ethics and Scientific Review Committee and by
the ethics committee of the London School of Hygiene and
Tropical Medicine. Written consent was sought from all par-
ticipants or their parents or guardians if under 18 years.
ORF sampling
The (Oracol (S10, Malvern Medical Developments Lim-
ited) ORF sampling kit) was used. In Connaught blood
bank the oral swabs were demonstrated by blood bank
staff and then self-administered by donors. The swab was
run along the upper and lower gum margins on either
side of the mouth for 30 seconds each (2 min total) before
returning it to the sampling tube. Samples were tested on
receipt or stored at –208C within a day of collection.
For the Kerry Town survivors and the community
controls the oral swabs were demonstrated by the field
staff and then self-administered, with adults helping chil-
dren. Each swab was rubbed firmly on the gums for 90
seconds, sealed, put in a cool box, transferred daily to the
laboratory, and tested on receipt or stored at –208C as
above.
Sample handling
Whole blood samples from potential donors were sepa-
rated within 24 hours of venesection. All plasma samples
Fig. 1. Recruitment process for volunteer convalescent donors seen first at the 34th Regimental Military Hospital Wilberforce
Freetown (MH34) before referral to the Blood Bank, National Safe Blood Service, Connaught Hospital, Freetown. 134th Regiment
Military Hospital, Wilberforce, Freetown, Sierra Leone. 2Sierra Leone Association of Ebola Survivors (SLAES). 3Compensation for
cost of attendance of 40,000 Sierra Leone Leones (SLL, $8 USD). 4Anemia, HBsAg, anti-HCV, anti-HIV, and antibody to syphilis.
5HBV infection excluded three donors; compensation of 80,000SLL ($16 USD) for attendance. 6Current well-being; vital signs
including temperature, height, and weight; research samples including ORF sampling by Oracol device; blood drawn in tempus
tubes, vacutainer PPT tubes, and EDTA tubes. 7Candidate donors returned to NSBS Blood Bank for first and subsequent aphere-
sis and received compensation for each apheresis of 300,000 SLL ($60 USD).
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received in Public Health England Colindale were tested
for EBOV RNA.15 Fresh ORFs or frozen ORFs that had
been thawed at room temperature were extracted by add-
ing 1 mL of transport medium (TM) to the tube, agitating
the swab in the TM within the tube, removing the swab
with a circular motion, dispelling ORF and TM from the
swab to provide the ORF extract, which remained in the
tube. Plasma samples and ORF extracts were stored at 48C
for up to 24 hours to allow testing before long-term stor-
age at –208C.
EIAs
Three solid-phase microplate EIAs were formulated, based
on the EBOV Mayinga GP antigen (rGPdTM, IBT Bioservi-
ces, Inc., USA Cat. 0501-016). In brief, the first was an
immunoglobulin (Ig)G-specific reverse capture assay (G-
capture EIA) using horseradish peroxidase (HRP)-labeled
EBOV GP. The second was a simultaneous competitive
assay (competitive EIA) using HRP-labeled monoclonal
antibody (MoAb; 4G7) raised against EBOV GP. The third
was a double-antigen bridging assay (DABA) using HRP-
EBOV GP performed qualitatively or quantitatively to
measure antibody to EBOV GP (full details of assays, criti-
cal reagents, and information for use leaflets in the Sup-
plementary Information, available as supporting
information in the online version of this paper). Both lat-
ter assays would be expected variously to detect IgM anti-
body, the competitive less so because of expected
antibody low avidity in acute infection, the DABA more so
because of the pentameric nature of IgM.
The positive control for the first two kits was plasma
from a UK EVD survivor infected in Sierra Leone taken 1.5
months after discharge. The DABA EIA used a pool of five
reactive donor plasmas attributed 1000 arbitrary units/mL
(au/mL). The negative control plasma came from unex-
posed UK blood donors.
Normalized optical density measures
Optical densities (ODs) were “normalized” as the ratio
between the test sample and the cut-off. For G-capture and
DABA, where a reaction is defined by a test sample giving
an OD of at least the kit cutoff, the normalized optical den-
sity (NOD) value is derived by test sample OD/cutoff OD.
For the competitive EIA, where a reaction is defined
by a test sample giving an OD of not more than the kit
cutoff, the NOD value is derived by cutoff OD/test sample
OD. Samples giving NOD of at least 1.0 are reactive.
Neutralizing antibody
The ability of a sample to neutralize the propagation of a
single-cycle infectious EBOV GP pseudo-type, as previ-
ously described,16 was used to investigate a selected panel
of CP samples (details in Supplementary Information). In
brief, the envelope-deficient human immunodeficiency
virus (HIV)-1 backbone pSG3Denv from the NIH AIDS
reagents repository (https://www.aidsreagents.org/) was
complemented with the Ebola GP expressed in (pcDNA3.1
from Thermofisher). The Ebola GP is derived from the
KP096421 early strain to which the coding changes
appearing later in the epidemic (A81V, I317V, T229A, and
N551D) were introduced. All analyses were performed in
triplicate and repeated. The neutralizing ability of a sam-
ple was expressed as that dilution of plasma that provided
a 50% reduction of virus infection (IC50).
Sample size and statistical analysis
The size of the potential donor panel was determined by
the need for plasma for a planned therapeutic interven-
tion study. Within- and between-assay variability was
assessed as the percentage of coefficient of variation (CV;
i.e., standard deviation/mean) using paired testing of
samples and from repeat testing of the positive kit control
across runs. Results from different assays (DABA, G-
capture, competitive) run on the same samples as well as
G-capture run on paired plasma and ORF samples were
compared by calculating R2 values (square of the correla-
tion coefficient) and as percentage agreement.
RESULTS
Test performance
For the G-capture EIA, replicate testing within plates of
222 analytes (plasma or ORF) from the potential donors,
Fig. 2. Correlation between paired ORF and plasma reactivity,
expressed as raw OD, from 10 convalescent donors tested in
the G-capture EIA at Connaught Blood Bank, Freetown
(R250.822 from linear regression). Linear regression line on
logged titers is shown.
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gave a mean CV of 2.9%; replicate testing of ORF samples
from survivors and community controls gave an average
CV of 8.0% within plates (23 samples) and 17.9% between
plates (104 samples). For the competitive EIA, replicate
testing within plates of 127 plasma samples from potential
donors gave a mean CV of 9.1%. For the quantitative
DABA on repeat testing the mean CV was 13%, the cali-
bration plots demonstrated a CV of approximately 8%.
Control populations
Forty-four ORF and serum samples were tested in dupli-
cate at Medical Research Council, The Gambia. With a
cutoff of kit mean negative plus 0.1, no sample was con-
sidered reactive. The 16 serum samples with highest OD
reactions were retested in the competitive EIA; all were
unreactive.
In Sierra Leone, using the same cutoff of mean nega-
tive plus 0.1 OD, ORF from 338 of 339 individuals with no
known exposure to EBOV infection were unreactive, giving
a specificity of 99.7% (95% confidence interval [CI],
98.4%-99.9%). The one reactive sample (NOD5 1.4) was
unreactive on further duplicate retesting. All other sam-
ples had NOD of less than 0.7. Among the 116 PCR-
confirmed survivors from Kerry Town Ebola Treatment
Center, 113 ORF samples were reactive on a single test,
giving a sensitivity of 97.4%, (95% CI, 92.5%-99.5%).
Potential donors
Field testing of paired plasma and ORF samples from 10
convalescent donors tested using the G-capture EIA at
Connaught Blood Bank in May 2015 demonstrated a clear
correlation between the reactivity of plasma and ORF (Fig.
2; R25 0.822). Tested at Connaught at the same time, 36 of
37 convalescent donor plasma samples, were reactive in
both G-capture and competitive EIAs, with correlated
reactivity levels (Fig. 3A; R25 0.625). Further initial and
repeat retesting was carried out at Public Health England
Colindale. All 115 plasma samples were retested for EBOV
RNA on receipt in the UK; all were negative. Eighty-eight
paired plasma and ORF samples showed good correlation
Fig. 3.
Fig. 3. (A) Correlation of NOD in the competitive and the G-
capture EIAs of 37 donor samples field tested in Connaught
Blood Bank, Freetown (R250.625 from linear regression).
() Samples from donors selected for further attendance.
One sample is concordantly unreactive (). () Reactivities
of the two WHO standards (15/262 top left; 15/220 bottom
right). (B) Correlation between NOD reactivity of 88 paired
ORF and plasma samples in the G-capture EIA from donors
taken at first attendance (R250.795). One ORF sample had a
NOD value less than 1.0 (, 0.78). () Two dually reactive
plasmas with anomalously low ORF NODs. Linear regression
line on logged titers is shown. (C) Correlation between G-
capture and competitive EIAs, expressed as log NOD values,
of 115 first-attendance plasma samples (R250.582). Three
samples are concordantly unreactive in both EIAs (). Two
samples are discordantly unreactive (), one is just below
the cutoff in the G-capture, and the other is just below cut-
off in the Competitive EIA (see Table 1). Linear regression
line on logged titers is shown.
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in reactivity on the G-capture EIA (R2 50.795 using linear
regression; Fig. 3B). One ORF sample was unreactive
(NOD, 0.78), giving a sensitivity of ORF compared to
plasma of 87 of 88, 98.9% (95% CI, 93.8%-99.97%). Two
ORF samples, although reactive, had lower reactivity in
the ORF G-capture test than expected from the plasma
results (Fig. 3B). They had a low level of IgG in the ORF as
sampled (<3 mg/L). One of these donors (ORF NOD, 3.2;
plasma NOD, 12.0) had provided an unpaired ORF 3 days
earlier which gave a NOD of 10.0.
Plasma samples from the 115 donors were tested in
the G-capture, competitive, and DABA EIAs: 110 were con-
cordantly positive in all three EIAs, three were concor-
dantly unreactive in all three EIAs, and two samples were
below the cutoff in one of the three EIAs but reactive in
the other two (Table 1). The overall agreement between
the three assays was therefore 113 of 115 (98.2%; 95% CI,
93.9%-99.8%) and the sensitivity of the assays was 111 of
115 (96.5%; 95% CI, 91.3%-99.0%) for G-capture and com-
petitive EIAs and 112 of 115 (97.4%; 95% CI, 92.6%-99.4%)
for DABA. Reactivity correlated between competitive and
G-capture EIAs (Fig. 3C).
EBOV GP antibody reactivity was measured in the
quantitative DABA EIA (Fig. 4). The three samples concor-
dantly unreactive in the two screening EIAs, had undetect-
able EBOV GP antibody in the qualitative DABA EIA. The
measurable antibody in the remaining 112 plasma sam-
ples varied over 2 3 log, from 50 to 3624 au/mL with a
geometric mean titer (GMT) of 392 au/mL. The 29 sam-
ples with reactivity in the upper quartile of the capture
EIA had GMT 745 au/mL, the 29 in the upper quartile of
the competitive EIA had a GMT of 838 au/mL, and the 20
in both upper quartiles had a GMT of 934 au/mL. The
subset of 25 samples chosen for investigation of neutraliz-
ing antibody had DABA antibody levels ranging from 200
to more 4000 au/mL reflecting the range of reactivity of
donor samples in this assay. There was a close correlation
between DABA reactivity and IC50 titers of neutralizing
antibody (R25 0.7633, Fig. 5B). A similar correlation
between the level of neutralizing antibody and reactivity
in the G-capture EIA was also seen for the paired plasmas
(R25 0.6794, Fig. 5A) and ORFs from 21 of the same donor
samplings where ORF data were available (R25 0.5700,
Fig. 5C). The neutralization IC50 of both the first (#79
NIBSC 15/220) and the second (#92 NIBSC 15/262) WHO
standards are as shown at 162 and 192, respectively (Figs.
5A and 5B).
DISCUSSION
We have shown that recruitment and screening of poten-
tial CP donors to exclude seronegative individuals and to
select those with higher antibody levels is possible in a
resource-poor setting during an EVD outbreak. Further-
more, the high sensitivity and specificity of the tests devel-
oped and the comparable performance of the G-capture
EIA when used on ORFs have implications beyond the
identification of donors, as they enable large-scale nonin-
vasive serologic studies.14
Seronegative individuals were, however, rare among
potential donors (3/115). Although all potential donors
TABLE 1. Details of the five first-time donor plasma samplings where an EIA NOD was less than 1.0 in one or more
of the three EIAs*
Sample identity
G-capture EIA Competitive EIA
DABA EIA
(au/mL) CommentRaw OD NOD Raw OD NOD
Donor 1 0.02 0.15 3.20 0.43 <35† PCR cycle threshold 20 in holding unit, undetectable at 48 and
72 hr later when retested after transfer to ETU.
Donor 2 0.02 0.11 2.58 0.54 <35† No record of PCR found nationally for this donor by name within
4 days of the date of reported admission to an ETU.
Donor 3 0.07 0.38 2.53 0.55 <35† No record of PCR found nationally for this donor by name within
4 days of the date of reported admission to an ETU .
Donor 4 0.17 0.99 1.00 1.38 112 Recorded PCR positive (though discrepancy in sex and age in
records) no address provided.
Donor 5 0.39 2.24 1.57 0.88 64 PCR-positive cycle thresholds 34 and 37 in two tests taken a
day apart.
Positive control 3.65 20.87 0.14 18.26 1000 UK 1 plasma used for both G-capture and competitive EIAs. A
pool of highly reactive plasma ascribed to contain 1000 au
used for DABA.
Negative control 0.07 0.41 2.63 0.53 <35† Pooled normal human plasma from UK blood donors.
Cutoff 0.17 1.00 1.39 1.00 Not
applicable
Defined for G-capture by mean OD-negative controls10.1 OD.
Defined for competitive EIA by comparison with 50% inhibition
of label binding.
* Plasma samples from Donors 1-3 inclusive were unreactive in any of the three tests used. Plasma sample from Donor 4 was unreactive in
the G-capture EIA and plasma sample from Donor 5 was unreactive in the competitive EIA, both plasmas from Donors 4 and 5 contained
detectable antibody to EBOV GP in the DABA EIA.
† Lower limit of detection in the run.
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possessed certificates indicating discharge from an Ebola
treatment unit (ETU), in the societal turmoil of an ongo-
ing epidemic and resulting deprivation it is not surprising
that certification may not be secure. Although recruitment
was facilitated by certification and financial incentive, it is
clearly appropriate to use serology to qualify donors for
therapeutic purposes. The seronegative donor of Plasma
Sample 1 (Table 1) was diagnosed before admission to the
ETU with a high viral load, which became undetectable
within 48 hours suggesting an erroneous first PCR proce-
dure. On further inquiry, no record of EBOV PCR testing
could be found nationally for the seronegative donors of
Plasma Samples 2 and 3. If these three are truly seronega-
tive as these data would infer, the G-capture EIA identified
111 of 112 (99.1%; 95% CI, 95.1%-99.98%).
Oral fluid testing provides acceptable noninvasive
sampling, used widely in clinical virology12 and is valuable
in acute outbreaks and seroepidemiologic studies. The
ORF EIA also correlated with EBOV candidate vaccine
response in UK volunteers.17 The negative G-capture
results from a nonexposed population in The Gambia
indicated good specificity. This was confirmed in the
unexposed community controls from Sierra Leone (338/
339 negative; specificity, 99.7%) while the sensitivity of the
G-capture EIA on ORF remained high (113/116 Kerry
Town EVD survivors positive; sensitivity, 97.4%).14 Fur-
thermore, the clear association between reactivity of ORF
and plasma (Figs. 2 and 3B) demonstrates that ORF is
appropriate for investigating the spread of EBOV in
diverse communities as well as selection of seropositive
donors. Previous studies were unable to detect EBOV anti-
body in ORF samples11 reflecting the poor sensitivity of
indirect EIAs for ORF studies.18 This is not the case for
reverse G-capture EIAs. However, the ORF sample must
be taken adequately to avoid false negatives from low-
ORF IgG levels; it would not normally be possible in the
field to check total IgG levels in the ORF.
A competitive EIA incorporating a MoAb to a well-
defined neutralizing epitope9 confirmed the specificity of
the ORF G-capture EIA, but requires a plasma sample.
The use of EIAs of different format has long been consid-
ered advantageous in the terms of specificity19 and this
same principle should apply to EBOV serology. Choice of
the EBOV GP antigen for serology was driven by availabil-
ity, by the previous selection of this GP for vaccine studies
and the generation of protective murine MoAb.9 This,
however, does not imply that antibody to EBOV GP is nec-
essarily the only therapeutic component of CP.
Having an antigen-coated solid phase and a directly
conjugated GP, it was a natural extension to develop a
double-antigen bridging EIA for antibody quantification.
Measurement of the level of reactivity in a capture or
competitive assay has subtly different implications. A cap-
ture assay reaction depends on the proportion of the anti-
body present in the analyte that recognizes the antigen
and the avidity with which the antibody interaction
occurs. A competitive assay depends on the concentration
of antibody present in the analyte and the avidity and spe-
cificity of that antibody. Usually a strong reaction in one
EIA correlates with a strong reaction in the other EIA, but
not necessarily with a direct linear relationship (Figs. 3A
and 3C). When antibody to EBOV GP was quantified in
the DABA EIA, levels differed widely between individuals
and many survivors had very low levels of measurable
antibody to GP. This suggests that alternative host deter-
minants such as the cytotoxic T-lymphocyte response
may be more important for survival and recovery than the
Fig. 4. Anti-EBOV GP levels in 115 seropositive convalescent
donor plasmas, expressed as log10 au/mL, measured in the
DABA EIA. Results are shown for the entire cohort (All)
superimposed with the first (15/220, lower of the two) and
second (15/262, upper of the two) WHO EBOV standards ()
and for those in either of the top quadrants for the G-
capture (Capture UQ) or for the competitive EIA (Competi-
tive UQ) and for those plasma samples reacting in both top
quadrants of the G-capture and the competitive EIAs (In
both UQ). Horizontal bars represent geometric mean values
anti-EBOV GP in au/mL.
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humoral response.8 It also begs the question whether EVD
survivors with low antibody levels are more susceptible to
viral persistence or reactivation.
Both the G-capture and the competitive EIAs allowed
selection of donors with high-level antibody (Fig. 4) quan-
tified by DABA EIA, which in turn measures total antibody
to EBOV GP. This selection, however, reduced the number
of suitable donors available, so having a noninvasive ini-
tial screening method that could be used more widely was
considered particularly useful. The range of antibody lev-
els we observed across the cohort may explain the lack of
clinical benefit4 found with the use of unselected CP in
the trial in Guinea. Quantification of antibody to EBOV GP
in DABA correlated with the measurement of biologically
determined neutralizing antibody. Both assays also ranked
the two WHO standards in the expected order of potency
and the observed neutralization IC50 titers were in agree-
ment with published data.20 We believe that these obser-
vations indicate that the DABA EIA was suitable for
quantifying biologically active antibody in the field. If the
effect of CP depends on antibody dosing,10 it will be inter-
esting to quantify neutralizing antibody in the full cohort
of Sierra Leone donors.
The three different EIAs we have developed, their bio-
logic plausibility, correlation with neutralizing antibody,
and the excellent performance of the G-capture EIA on
ORF providing a sensitive, specific, and noninvasive way
of determining the EBOV serologic status of individuals,
provide a suitable epitaph to our much loved and sadly
missed colleague Dr Dhan Samuel.
APPENDIX A
Ebola_CP Consortium Investigators
The Ebola_CP: The Consortium Investigators for Ebo-
la_CP (Convalescent Plasma for Early Ebola Virus Dis-
ease in Sierra Leone) are M.G. Semple (Consortium
Lead Investigator) and J.T. Scott, (both Institute of
Translational Medicine and NIHR Health Protection
Research Unit in Emerging and Zoonotic Infections
University of Liverpool, Liverpool, UK); S.M. Gevao
(Country Lead Investigator), F. Sahr (Country Deputy
Lead Investigator), C.P. Cole and J. Russell (all College
of Medicine and Allied Health Sciences, Freetown,
Sierra Leone); S. Baker, O. Kargbo, and P. Kamara (all
National Safe Blood Service, Connaught Hospital, Min-
istry of Health & Sanitation, Freetown, Sierra Leone);
M. Lado and C.S. Brown (King’s Sierra Leone Health
Partnership, King’s Health Partners & King’s College
London, London, UK); J. van Griensven, R. Ravinetto,
and Y. Claeys (all Institute of Tropical Medicine, Ant-
werp, Belgium); R.S. Tedder, R. Gopal, and T.J.G.
Brooks (National Infection Service, Public Health
England, London, UK); C.C. Smith (Health Protection
Scotland, UK); H.A. Doughty (NHS Blood and Trans-
plant & College of Medical and Dental Sciences, Uni-
versity of Birmingham, Birmingham, UK); A. Mari Saez
and M. Borchert (both Institute for Tropical Medicine
and International Health, Charite, Berlin, Germany);
A.H. Kelly (Department of Sociology, Philosophy and
Anthropology, Exeter University, Exeter, UK); J.K. Baillie
(The Roslin Institute, University of Edinburgh, Edin-
burgh, UK); N. Shindo, and D. Pfeifer (Department of
Fig. 5. Anti-EBOV GP levels in a selected panel of 25 convalescent donors. Plasma antibody measured by pseudotype neutraliza-
tion (interpolated IC50 neutralization titers) correlates with plasma reactivity in the G-capture EIA (expressed as NODs, A,
R250.6794), with quantified plasma reactivity in the DABA EIA (expressed in au/mL, B, R25 0.7633) and with paired ORF (21
ORF samples only) reactivity in G-capture EIA (expressed as NODs, C, R250.5700). () IC50 titers (A, B) for first (15/220 bottom
left) and the second (15/252 bottom right) WHO standards at 162 and 192, respectively. Linear regression lines on logged titers
are shown.
TEDDER ET AL.
1296 TRANSFUSION Volume 58, May 2018
Pandemic and Epidemic Diseases, World Health Orga-
nization, Geneva, Switzerland); D.L. Hoover (Clini-
calRM Inc., Hinckley, OH); W.A. Fischer II and D.A.
Wohl (both Department of Medicine, University of
North Carolina, Chapel Hill, NC); N.M. Thielman
(Duke University School of Medicine, Durham, NC);
P.W. Horby and L. Merson (Nuffield Department of
Medicine, University of Oxford, Oxford, UK); and P.G.
Smith and T. Edwards (Medical Research Council Trop-
ical Epidemiology Group, London School of Hygiene &
Tropical Medicine, London, UK).
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